Effects of Losartan-based therapy on the incidence of end-stage renal disease and associated costs in type 2 diabetes mellitus: A retrospective cost-effectiveness analysis in the United Kingdom

Current Therapeutic Research - Clinical and Experimental

Volumn 66, Issue 6, 2005, Pages 475-485

  Vora, Jiten ^a   Carides, George ^b   Robinson, Paul ^c  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^b MERCK RESEARCH LABORATORIES   (United States)

^c Merck Sharp & Dohme Limited   (United Kingdom)

Author keywords

Cost; Diabetic nephropathy; Economic analysis; End stage renal disease; ESRD; Losartan

Indexed keywords

LOSARTAN;

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; HUMAN; INCIDENCE; KIDNEY FAILURE; NATIONAL HEALTH SERVICE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; SURVIVAL; UNITED KINGDOM;

EID: 33244492501     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.curtheres.2005.12.005     Document Type: Article

References (21)

1. Available at UK Transplant Fact sheet: The cost-effectiveness of transplantation Accessed January 28, 2005 2003 UK Transplant London, UK
2. Brenner B.M., Cooper M.E., and de Zeeuw D. RENAAL Study Investigators Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med. 345 2001 861 869
3. Brenner B.M., Cooper M.E., and de Zeeuw D. RENAAL Study Investigators The losartan renal protection study - rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) J Renin Angiotensin Aldosterone Syst 1 2000 328 335
4. Lewis E.J., Hunsicker L.G., Clarke W.R. Collaborative Study Group^ Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med. 345 2001 851 860
5. Vora J.P., Robinson P.J., and O'Hare P. Economic implications of the RENAAL study in the United Kingdom Diabet Med. 20 Suppl 2 2003 89
6. Caro J., Klittich W., and McGuire A. The West of Scotland coronary prevention study: Economic benefit analysis of primary prevention with pravastatin BMJ 315 1997 1577 1582
7. 2004 Scottish Renal Association Scottish Renal Registry Report 2001 Scottish Renal Association Information and Statistics Division Edinburgh, Scotland
8. Available at: Wordsworth S., and Ludbrook A. Comparability of costing across countries: Does the approach matter? Accessed Presented at: Developing Economic Evaluation Methods (DEEM) Meeting April 15-16, 2003; Aberdeen, UK February 1, 2005
9. Efron B., and Tibshirani R.J. An Introduction to the Bootstrap 1993 Chapman and Hall New York, NY
10. Available at: US Dept of Health and Human Services (DHHS) National service framework for renal disease [DHHS Web site] Accessed November 27, 2005
11. Engemann J.J., Friedman J.Y., and Reed S.D. Clinical outcomes and costs due to Staphylococcus aureus bacteremia among patients receiving long-term hemodialysis Infect Control Hosp Epiderniol. 26 2005 534 539
12. Metcalfe W., Khan I.H., and Prescott G.J. Hospitalization in the first year of renal replacement therapy for end-stage renal disease QJM 96 2003 899 909
13. Herman W.H., Shahinfar S., and Carides G.W. Losartan reduces the costs associated with diabetic end-stage renal disease: The RENAAL study economic evaluation Diabetes Care 26 2003 683 687
14. Szucs T.D., Sandoz M.S., and Keusch G.W. The cost-effectiveness of losartan in type 2 diabetics with nephropathy in Switzerland-an analysis of the RENAAL study Swiss Med Wkly 134 2004 440 447
15. Available at: National Institute for Clinical Excellence (NICE) Management of type 2 diabetes. Renal disease: Prevention and early management [NICE Web site] Accessed December 1, 2005
16. [published correction appears in Lancet. 2000;356:860] Heart Outcomes Prevention Evaluation Study Investigators Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy Lancet 355 2000 253 259
17. Strippoli G.F., Craig M., and Deeks J.J. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: Systematic review BMJ 329 2004 828
18. [published correction appears in JAMA. 2003;290:197] Chobanian A.V., Bakris G.L., and Black H.R. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection Evaluation, and Treatment of High Blood Pressure and the National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report JAMA 289 2003 2560 2572
19. Arauz-Pacheco C., Parrott M.A., Raskin P., and American Diabetes Association Treatment of hypertension in adults with diabetes Diabetes Care 26 Suppl 1 2003 S80 S82
20. Doulton T.W., He F.J., and MacGregor G.A. Systematic review of combined angiotensinconverting enzyme inhibition and angiotensin receptor blockade in hypertension Hypertension 45 2005 880 886
21. Palmer A.J., Annemans L., and Roze S. Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease Diabetes Care 27 2004 1897 1903